RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Eiger BioPharmaceuticals Stock

Eiger BioPharmaceuticals Revenue 2024

Eiger BioPharmaceuticals Revenue

25.72 M USD

Ticker

EIGR

ISIN

US28249U1051

WKN

A2AF9X

In 2024, Eiger BioPharmaceuticals's sales reached 25.72 M USD, a 63.08% difference from the 15.77 M USD sales recorded in the previous year.

The Eiger BioPharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e165.059,55
2028e56.9427,67
2027e36.8742,73
2026e35.0444,96
2025e33.3147,31
2024e25.7261,26
202315.7799,90
202213.4886,42
202112.1493,90
2020--
2019--
2018--
2017--
2016--
2015--
2014--
2013--
2012--
2011--
2010--

Eiger BioPharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Eiger BioPharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eiger BioPharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eiger BioPharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Eiger BioPharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Eiger BioPharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Eiger BioPharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eiger BioPharmaceuticals’s growth potential.

Eiger BioPharmaceuticals Revenue, EBIT and net profit per share

DateEiger BioPharmaceuticals RevenueEiger BioPharmaceuticals EBITEiger BioPharmaceuticals Net Income
2029e165.05 M undefined599.34 M undefined59.33 M undefined
2028e56.94 M undefined14.42 M undefined5.43 M undefined
2027e36.87 M undefined-4.21 M undefined-4.08 M undefined
2026e35.04 M undefined-5.14 M undefined-150,960 undefined
2025e33.31 M undefined-6.35 M undefined-5.43 M undefined
2024e25.72 M undefined-21.97 M undefined-23.55 M undefined
202315.77 M undefined-71.78 M undefined-74.96 M undefined
202213.48 M undefined-92.74 M undefined-96.78 M undefined
202112.14 M undefined-76.94 M undefined-33.92 M undefined
20200 undefined-62.15 M undefined-65.05 M undefined
20190 undefined-68.9 M undefined-70.25 M undefined
20180 undefined-51.05 M undefined-52.39 M undefined
20170 undefined-41.52 M undefined-42.45 M undefined
20160 undefined-46.12 M undefined-47.09 M undefined
20150 undefined-12.97 M undefined-13.32 M undefined
20140 undefined-1.52 M undefined-1.52 M undefined
20130 undefined-19.96 M undefined-23.96 M undefined
20120 undefined-15.95 M undefined-16.21 M undefined
20110 undefined-6.03 M undefined-6.99 M undefined
20100 undefined-6.03 M undefined-6.99 M undefined

Eiger BioPharmaceuticals stock margins

The Eiger BioPharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eiger BioPharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eiger BioPharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Eiger BioPharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Eiger BioPharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Eiger BioPharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Eiger BioPharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eiger BioPharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eiger BioPharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eiger BioPharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Eiger BioPharmaceuticals Margin History

Eiger BioPharmaceuticals Gross marginEiger BioPharmaceuticals Profit marginEiger BioPharmaceuticals EBIT marginEiger BioPharmaceuticals Profit margin
2029e99.9 %363.13 %35.95 %
2028e99.9 %25.32 %9.54 %
2027e99.9 %-11.4 %-11.05 %
2026e99.9 %-14.67 %-0.43 %
2025e99.9 %-19.05 %-16.32 %
2024e99.9 %-85.42 %-91.55 %
202399.9 %-455.07 %-475.26 %
202286.42 %-687.98 %-717.95 %
202193.9 %-633.77 %-279.41 %
202099.9 %0 %0 %
201999.9 %0 %0 %
201899.9 %0 %0 %
201799.9 %0 %0 %
201699.9 %0 %0 %
201599.9 %0 %0 %
201499.9 %0 %0 %
201399.9 %0 %0 %
201299.9 %0 %0 %
201199.9 %0 %0 %
201099.9 %0 %0 %

Eiger BioPharmaceuticals Aktienanalyse

What does Eiger BioPharmaceuticals do?

Eiger BioPharmaceuticals Inc is a US biopharmaceutical company that specializes in developing therapeutics for rare and serious diseases. It was founded in 2008 and is headquartered in Palo Alto, California. The company's history is closely tied to the discovery of hepatitis C medications, and their business model focuses on developing antiviral therapies for rare and severe diseases. They have multiple divisions dedicated to different therapeutic areas, including hepatitis C, hepatitis D, fibrosis, and lysosomal storage disorders. They currently offer several products, including Zokinvy for chronic hepatitis C infection and Lambda for hepatitis D. They have also formed strategic partnerships with other pharmaceutical companies to support the development and commercialization of their products. Overall, Eiger BioPharmaceuticals Inc is known for its innovative approach and commitment to improving treatment options for patients with serious medical needs. Eiger BioPharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Eiger BioPharmaceuticals's Sales Figures

The sales figures of Eiger BioPharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Eiger BioPharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Eiger BioPharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Eiger BioPharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Eiger BioPharmaceuticals stock

How much revenue did Eiger BioPharmaceuticals generate this year?

Eiger BioPharmaceuticals has achieved a revenue of 25.72 M USD this year.

How much was the turnover of the company Eiger BioPharmaceuticals compared to the previous year?

The revenue of Eiger BioPharmaceuticals has increased by 63.08% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Eiger BioPharmaceuticals?

The revenue of Eiger BioPharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Eiger BioPharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Eiger BioPharmaceuticals so important for investors?

The revenue of Eiger BioPharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Eiger BioPharmaceuticals pay?

Over the past 12 months, Eiger BioPharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eiger BioPharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eiger BioPharmaceuticals?

The current dividend yield of Eiger BioPharmaceuticals is .

When does Eiger BioPharmaceuticals pay dividends?

Eiger BioPharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eiger BioPharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eiger BioPharmaceuticals located?

Eiger BioPharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eiger BioPharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eiger BioPharmaceuticals from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Eiger BioPharmaceuticals pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Eiger BioPharmaceuticals in the year 2023?

In the year 2023, Eiger BioPharmaceuticals distributed 0 USD as dividends.

In which currency does Eiger BioPharmaceuticals pay out the dividend?

The dividends of Eiger BioPharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Eiger BioPharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Eiger BioPharmaceuticals

Our stock analysis for Eiger BioPharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eiger BioPharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.